Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring
Adenocarcinoma of Lung
/ genetics
Aged
B7-H1 Antigen
Brain Neoplasms
/ complications
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Class I Phosphatidylinositol 3-Kinases
/ genetics
Exons
High-Throughput Nucleotide Sequencing
Humans
Lung Neoplasms
/ genetics
Male
Piperidines
Protein Kinase Inhibitors
/ therapeutic use
Proto-Oncogene Proteins c-met
/ genetics
Pyridazines
Pyrimidines
lung adenocarcinoma
Journal
Cold Spring Harbor molecular case studies
ISSN: 2373-2873
Titre abrégé: Cold Spring Harb Mol Case Stud
Pays: United States
ID NLM: 101660017
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
26
07
2020
accepted:
24
09
2020
entrez:
18
12
2020
pubmed:
19
12
2020
medline:
15
9
2021
Statut:
epublish
Résumé
Tyrosine kinase inhibitors (TKIs) have transformed the standard of care in lung cancer. A number of TKIs have been discovered that specifically target oncogenes, including MET receptor tyrosine kinase. Second-generation MET TKIs are showing improved efficacy over first-generation TKIs. Herein, we report a case of a patient with metastatic lung adenocarcinoma harboring a
Identifiants
pubmed: 33335011
pii: mcs.a005785
doi: 10.1101/mcs.a005785
pmc: PMC7784494
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Piperidines
0
Protein Kinase Inhibitors
0
Pyridazines
0
Pyrimidines
0
tepotinib
1IJV77EI07
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
Proto-Oncogene Proteins c-met
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218545
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA209978
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA247471
Pays : United States
Informations de copyright
© 2020 Roth et al.; Published by Cold Spring Harbor Laboratory Press.
Références
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Front Oncol. 2019 Aug 02;9:717
pubmed: 31428584
N Engl J Med. 2020 Sep 3;383(10):931-943
pubmed: 32469185
J Thorac Oncol. 2017 Jan;12(1):152-156
pubmed: 27693535
Cancer Res. 2003 Oct 1;63(19):6272-81
pubmed: 14559814
J Thorac Oncol. 2016 Sep;11(9):1493-502
pubmed: 27343443
Exp Mol Med. 2017 Mar 24;49(3):e307
pubmed: 28336955
Clin Cancer Res. 2020 Jun 1;26(11):2615-2625
pubmed: 32034073
Clin Cancer Res. 2013 Jun 1;19(11):2941-51
pubmed: 23553846
Cancer Res. 2005 Feb 15;65(4):1479-88
pubmed: 15735036
J Thorac Oncol. 2020 May;15(5):741-751
pubmed: 32169477
Lung Cancer. 2009 Feb;63(2):169-79
pubmed: 18672314
Oncol Res Treat. 2017;40(4):198-202
pubmed: 28324883
Onco Targets Ther. 2020 Jun 30;13:6245-6253
pubmed: 32669854
Cancer Treat Rev. 2020 Jul;87:102022
pubmed: 32334240
Ann Oncol. 2018 Oct 1;29(10):2085-2091
pubmed: 30165371
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Nat Med. 2020 Jan;26(1):47-51
pubmed: 31932802
Cancer Discov. 2015 Aug;5(8):842-9
pubmed: 25971939
J Thorac Oncol. 2019 Oct;14(10):1753-1765
pubmed: 31279006